Blues Plan Launches Value-Based Kidney Care Program

Blue Cross and Blue Shield of Minnesota recently launched a new value-based agreement with VillageHealth focused on certain members with chronic kidney disease (CKD) or end-stage renal disease (ESRD). By working with VillageHealth, a DaVita Inc. subsidiary, the Blues plan hopes to improve member outcomes and reduce their total cost of care.

The Centers for Disease Control and Prevention estimates that more than one in seven adults in the U.S. — or 37 million people — have CKD, but most of them do not realize it. When the kidneys are damaged, this can result in high blood pressure, heart disease, stroke and early death. If the condition is not treated, it can progress to ESRD, which requires a transplant or dialysis.

Program Will Coordinate Members’ Care

The program has a variety of components. VillageHealth and DaVita will collaborate with nephrologists and primary care physicians to coordinate care for plan members into an integrated plan. The program will launch an awareness campaign for primary care providers focused on improving screening for kidney disease, managing early-stage patients and offering appropriate referrals to nephrologists.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 16

FDA Grants Interchangeable Status to Humira Biosimilar; Payers Should Prepare Now for 2023 Launches

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image_NSCLC.jpg
November 16

New Tecartus FDA Approval for Adults With ALL Offers Welcome Therapeutic Option

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Specialty-Trend-Increase-Slows-Biosimilars-Are-Having-Impact.jpg
November 16

Prime Therapeutics Launches IntegratedRx – Oncology, Partners on MIP Accreditation

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today